Research Paper Volume 15, Issue 16 pp 8204—8219
PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer
Figure 5. The role of PTPRD mutation in GSEA and TIICs. (A) GSEA analysis of PTPRD mutation in LUAD. (B) GSEA analysis of PTPRD mutation in LUSC. (C) The relationship between the mutation status of PTPRD and immune cells in LUAD. (D) The relationship between the mutation status of PTPRD and immune cells in LUSC.